These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15105795)

  • 1. Enhancing oral contraceptive success: the potential of new formulations.
    Kaunitz AM
    Am J Obstet Gynecol; 2004 Apr; 190(4 Suppl):S23-9. PubMed ID: 15105795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for new oral contraceptive dosing.
    Williams JK
    Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
    Greco T; Graham CA; Bancroft J; Tanner A; Doll HA
    Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone.
    Shoupe D
    Obstet Gynecol; 1994 May; 83(5 Pt 1):679-85. PubMed ID: 8164925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM; Thomas CM; Borm GF; Rolland R
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral contraception: disadvantages of estrogen reduction].
    Denis C
    Contracept Fertil Sex (Paris); 1993 Jun; 21(6):481-8. PubMed ID: 12318238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
    Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
    Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating acne with oral contraceptives: use of lower doses.
    Huber J; Walch K
    Contraception; 2006 Jan; 73(1):23-9. PubMed ID: 16371290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral contraception: advantages of estrogen reduction].
    Cohen J
    Contracept Fertil Sex (Paris); 1993 Jun; 21(6):489-94. PubMed ID: 12318239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OC practice guidelines: minimizing side effects.
    Darney PD
    Int J Fertil Womens Med; 1997; Suppl 1():158-69. PubMed ID: 9168375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Third generation progestagens].
    Belaisch J; Eliakim V
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):287-93. PubMed ID: 12318226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Brenner P
    Contraception; 2006 Oct; 74(4):354; author reply 354-5. PubMed ID: 16982246
    [No Abstract]   [Full Text] [Related]  

  • 19. [Metrorrhagia caused by estrogen-progestin combinations].
    Erny R; Erny N
    Contracept Fertil Sex (Paris); 1994 Feb; 22(2):93-7. PubMed ID: 12319056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YAZ and the novel progestin drospirenone.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.